Building a Specialized Biobank for Portal Hypertension Patients with or without Liver Cirrhosis Using Clinical Data and Multi-Omics Technologies for Improved Diagnosis and Treatment

What this Trial Is About

Researchers are investigating portal hypertension and its serious complication, esophageal and gastric variceal bleeding EGVB, which has high risks of bleeding, rebleeding, and death. This observational study focuses on expanding a biobank for portal hypertension by extending clinical cohort data over time and collecting diverse biological samples. The aim is to improve understanding of the disease, especially in patients with cirrhotic and non-cirrhotic portal hypertension, through multi-omics and advanced data analysis techniques. The study observes patients with portal hypertension who either have liver cirrhosis or do not. Participants receive endoscopic treatments such as ligation and cyanoacrylate injection, which are standard procedures used to manage variceal bleeding. The study collects clinical and imaging data, including abdominal CT scans, to support the biobank and provide detailed medical information for research. Participants will be followed for up to one year to monitor outcomes like rebleeding rates, death, and complications related to portal hypertension. The study involves collecting medical histories, imaging results, and treatment responses to provide comprehensive data for analysis. This long-term follow-up and data collection support developing improved clinical decision tools using artificial intelligence and multi-omics technologies.

Construction of a Portal Hypertension Biobank